Keyword
in
Collection
Date
to
Download Folder

0 items

Houston Voice, No. 1005, January 28, 2000
File 005
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 1005, January 28, 2000 - File 005. 2000-01-28. University of Houston Libraries. University of Houston Digital Library. Web. December 15, 2017. http://digital.lib.uh.edu/collection/montrose/item/2595/show/2566.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(2000-01-28). Houston Voice, No. 1005, January 28, 2000 - File 005. Montrose Voice. University of Houston Libraries. Retrieved from http://digital.lib.uh.edu/collection/montrose/item/2595/show/2566

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 1005, January 28, 2000 - File 005, 2000-01-28, Montrose Voice, University of Houston Libraries, accessed December 15, 2017, http://digital.lib.uh.edu/collection/montrose/item/2595/show/2566.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 1005, January 28, 2000
Contributor
  • Hennie, Matthew A.
Publisher Window Media
Date January 28, 2000
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Rights In Copyright: This item is protected by copyright. Copyright to this resource is held by the creator or current rights holder, and the resource is provided here for educational purposes. It may not be reproduced or distributed in any format without permission of the copyright owner. Users assume full responsibility for any infringement of copyright or related rights.
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 005
Transcript JANUARY 28, 2000 • HOUSTON VOICE VIRACEPT nelfinavir mesylate tablets and oral powder Information for Patients About VIRACEPT* (Vl-ra-cept) Generic Name: nelfinavir (nel-FIN-na-veer) mesylate For the Treatment of Human Immunodeficiency Virus (HIV) Infection Please read this information carefully before taking VIRACEPT. Also, please read this leaflet each time you renew the prescription, just in case anything has changed. This is a summary and not a replacement for a careful discussion with your doctor You and your doctor should discuss VIRACEPT when you start taking this medication and at regular checkups. You should remain under a doctor's care when taking VIRACEPT and should not change or stop treatment without first talking with your doctor, WHAT IS VIRACEPT AND HOW DOES IT WORK? VIRACEPT is used in the treatment of people with human Immunodeficiency virus (HIV) infection. Infection with HIV leads to the destruction of CD4 T cells, which are important to the immune system. After a large number of CD4 ceils have been destroyed, the infected person develops acquired immune deficiency syndrome (AIDS). VIHACEPT works by blocking HIV protease (a protein-cutting enzyme), which is required for HIV to multiply. VIRACEPT has been shown to significantly reduce the amount of HIV in the blood. You should be aware, however, that the effect of VIRACEPT on HIV in the blood has not been correlated with long- term health benefits. Patients who took VIRACEPT also had significant increases in their CD4 cell count. VIRACEPT is usually taken together with other antiretroviral drugs such as Retrovir* (zidovudine, AZT), Epivir* (lamivudine. 3TC), or Zerit* (stavudine. d4T). Taking VIRACEPT in combination with other antiretroviral drugs reduces the amount 01 HIV in the body (viral load) and raises CD4 counts. VIRACEPT may be taken by adults, adolescents, and children 2 years ol age or older. Studies in infants younger than 2 years of age are now taking place. DOES VIRACEPT CURE HIV OR AIDS? VIRACEPT is not a cure for HIV infection or AIDS. The long-term effects of VIRACEPT are not known at this time. People taking VIRACEPT may still develop opportunistic infections or other conditions associated with HIV infection. Some of these conditions are pneumonia, herpes virus infections, Mycobacterium avium complex (MAC) infections, and Kaposi's sarcoma. It is not known whether VIRACEPT will help you live longer or reduce the number of infections or other illnesses that may occur There is no proof that VIRACEPT can reduce the risk of transmitting HIV to others through sexual contact or blood contamination. WHO SHOULD OR SHOULD NOT TAKE VIRACEPT? Together with your doctor, you need to decide whether VIRACEPT is appropriate for you. In making your decision, the following should be considered: Allergies: If you have had a serious allergic reaction to VIRACEPT, you must not take VIRACEPT. You should also inform your doctor, nurse, or pharmacist of any known allergies to substances such as other medicines, foods, preservatives, or dyes. If you are pregnant: The effects of VIRACEPT on pregnant women or their unborn babies are not known. If you are pregnant or plan to become pregnant, you should tell your doctor before taking VIRACEPT If you are breast-feeding: You should discuss with your doctor the best way to feed your baby. You should be aware that if your baby does not already have HIV, there is a chance that it can be transmitted through breast-feeding. Women should no! breast-feed if they have HIV. Children: VIRACEPT is available for the treatment of children 2 through 13 years of age with HIV, There is a powder form of VIRACEPT that can be mixed with milk, baby formula, or foods like pudding Instructions on how to take VIRACEPT powder can be found in a later section that discusses how VIRACEPT Oral Powder should be prepared. If you have liver disease: VIRACEPT has not been studied in people with liver disease. If you have liver disease, you should tell your doctor before taking VIRACEPT. Other medical problems: Certain medical problems may affect the use of VIRACEPT. Some people taking protease inhibitors have developed new or more serious diabetes or high blood sugar. Some people with hemophilia have had increased bleeding. It is not known whether the protease inhibitors caused these problems. Be sure to tell your doctor if you have hemophilia types A and B, diabetes mellitus, or an increase in thirst and/or frequent urination. CAN VIRACEPT BE TAKEN WITH OTHER MEDICATIONS? VIRACEPT may interact with other drugs, including those you take without a prescription You must discuss with your doctor any drugs that you are taking or are planning to take before you take VIRACEPT. Drugs you should not take with VIRACEPT: • Seldane" (tertenadine, for allergies) • Hismanal* (astemizole, for allergies) • Propulsid* (cisapride, for heartburn) • Cordarone"(amiodarone, for irregular heartbeat) • Quimdine (for irregular heartbeat), also known as Quinaglute*Cafdioquin*Quinidex*and others • Ergot derivatives (Cafergot* and others, for migraine headache) • Halcion* (triazolam) • Versed* (midazolam) Taking the above drugs with VIRACEPT may cause serious and/or life-threatening adverse everts. • Rifampin (for tuberculosis), also known as Rimactane*, Rifadin*, Rifater*, or Rifamate* This drug reduces blood levels of VIRACEPT Dose reduction required if you lake VIRACEPT with: Mycobutm" (rifabutin, for MAC); you will need to take a lower dose of Mycobutin. A change of therapy should be considered il you are taking VIRACEPT with: • Phenobarbital • Phenytoin (Dilantin" and others) • Carbamazepine (Tegretol* and others) These agents may reduce the amount of VIRACEPT in your blood and make it less effective. • Oral contraceptives ("the pill") If you are taking the pill to prevent pregnancy, you should use a different type of contraception since VIRACEPT may reduce the effectiveness of oral contraceptives. HOW SHOULD VIRACEPT BE TAKEN WITH OTHER ANTI-HIV DRUGS? Taking VIRACEPT together with other anti-HIV drugs increases their ability to fight the virus. It also reduces the opportunity for resistant viruses to grow. Based on your history of taking other anti-HIV medicine, your doctor will direct you on how to take VIRACEPT and other anti-HIV medicines. These drugs should be taken in a certain order or at specific times. This will depend on how many times a day each medicine should be taken. It will also depend on whether it should be taken with or without food. Nucleoside analogues: No drug interaction problems were seen when VIRACEPT was given with: • Retrovir (zidovudine. AZT) • Epivir (lamivudine, 3TC) • Zerit (stavudine. d4Tl • Videx* (didanosine, ddl) If you are taking both Videx (ddl) and VIRACEPT: Videx should be taken without food, on an empty stomach. Therefore, you should take VIRACEPT with lood one hour after or more than two hours before you take Videx. Nonnucleoside reverse transcriptase inhibitors (NNRTls): When VIRACEPT is taken together with: • Viramune* (nevirapine) The amount of VIRACEPT in your blood may be reduced Studies are now taking place to learn about the safety of combining VIRACEPT with Viramune. • Other NNRTls VIRACEPT has not been studied with other NNRTls. Other protease inhibitors: When VIRACEPT is taken together with: • Crixivan" (indinavir) The amount of both drugs in your blood may be increased. Currently, there are no safety and efficacy data available from the use of this combination. • Norvir™ (ritonavir) The amount of VIRACEPT in your blood may be increased. Currently, there are no safety and efficacy data available from the use or this combination. ■ Invirase* (saquinavir) The amount of saquinavir in your blood may be increased. If used in combination with saquinavir hard gelatin capsules at 600 mg three times daily, no dose adjustments are needed. Currently, there are no safety and efficacy data available from the use of this combination. WHAT ARE THE SIDE EFFECTS OF VIRACEPT? Like all medicines, VIRACEPT can cause side effects. Most of the side effects experienced with VIRACEPT have been mild to moderate. Diarrhea is the most common side effect in people taking VIRACEPT, and most adult patients had at least mild diarrhea at some point during treatment. In clinical studies, about 20% ot patients receiving VIRACEPT 750 mg (three tablets) three times daily had four or more loose stools a day. In most cases, diarrhea can be controlled using antidiarrheal medicines, such as Imodium" A-D (loperamide) and others, which are available without a prescription. Other side effects that occurred in 2% or more of patients receiving VIRACEPT include abdominal pain, asthenia, nausea, flatulence, and rash. There were other side effects noted in clinical studies that occurred in less than 2% of patients receiving VIRACEPT. However, these side effects may have been due to other drugs that patients were taking or to the illness itself. Except for diarrhea, there were not many differences in side effects in patients who took VIRACEPT along with other drugs compared with those who took only the other drugs. For a complete list of side effects, ask your doctor, nurse, or pharmacist. HOW SHOULD I TAKE VIRACEPT? VIRACEPT is available only with your doctor's prescription. The light blue VIRACEPT Tablets should be taken three times a day. VIRACEPT should always be taken with a meal or a light snack. You do not have to take VIRACEPT exactly every 8 hours. Instead, you can take it at normal times when you are eating. Take VIRACEPT exactly as directed by your doctor. Do not increase or decrease any dose or the number of doses per day. Also, take this medicine for the exact period of time that your doctor has instructed. Do not stop taking VIRACEPT without tint consulting with your doctor, even If you are leeiing better. Only take medicine that has been prescribed specifically for you. Do not give VIRACEPT to others or take medicine prescribed for someone else. The dosing of VIRACEPT may be different for you than for other patients. Follow the directions from your doctor, exactly as written on the label. The amount of VIRACEPT in the blood should remain somewhat consistent over time. Missing doses will cause the concentration of VIRACEPT to decrease; therefore, you should not miss any doses. However, if you miss a dose, you should take the dose as soon as possible and then take your next scheduled dose and future doses as originally scheduled. Dosing in adults (including children 14years of age and older) The recommended adult dose ot VIRACEPT is 750 mg (three tablets) taken three times a day. Each dose should be taken with a meal or light snack. Dosing in children 2 through 13 years of age The VIRACEPT dose in children depends on their weight. The recommended dose is 20 to 30 mg/kg (or 9 to 14 mg/pound) per dose, taken three times daily with a meal or light snack. This can be administered either in tablet form or, in children unable to take tablets, as VIRACEPT Oral Powder. Dose instructions will be provided by the child's doctor. The dose will be given three times daily using the measuring scoop provided, a measuring teaspoon, or one or more tablets depending on the weight and age of the child. The amount of oral powder or tablets to be given to a child is described in the chart below. Pediatric Dose to Be Administered Three Times Daily Body Weight Lb Number of level Scoops* Number of Level Teaspoons* Number of Tablets 7 to < 8.5 15.5 to <18.5 4 1 8.5 to <10.5 18.5 to <23 5 IV. 10.5 to <12 23 to <26.5 6 IV, 12 to <14 26.5 lo <31 7 IV. 14 to <16 31 to <35 8 2 16 to <18 35 to <39.5 9 2V. 18 to <23 39.5 to <50.5 10 2Vi 2 223 250.5 15 3V. 3 In measuring oral powder, the scoop or teaspoon should be level. ' 1 level scoop contains 50 mg of VIRACEPT. Use only the scoop provided with your VIRACEPT bottle. ' 1 level teaspoon contains 200 mg of VIRACEPT Note: A measuring teaspoon used for dispensing medication should be used for measuring VIRACEPT Oral Powder. Ask your pharmacist to make sure you have a medication dispensing teaspoon. How should VIRACEPT Oral Powder be prepared? The oral powder may be mixed with a small amount of water, milk, formula, soy formula, soy milk, dietary supplements, or dairy foods such as pudding or ice cream. Once mixed, the entire amount must be taken to obtain the full dose. Do not mix the powder with any acidic food or juice, such as orange or grapefruit juice, apple juice, or apple sauce, because this may create a bitter taste. Once the powder is mixed, it may be stored at room temperature or refrigerated for up to 6 hours. Do not heat the mixed dose once it has been prepared. Do not add water to bottles of oral powder. VIRACEPT powder is supplied with a scoop for measuring. For help in determining the exact dose of powder for your child, please ask your doctor, nurse, or pharmacist. VIRACEPT Oral Powder contains aspartame, a low-calorie sweetener, and therefore should not be taken by children with phenylketonuria (PKU). HOW SHOULD VIRACEPT BE STORED? Keep VIRACEPT and all other medicines out of the reach ot children. Keep bottle closed and store at room temperature (between 59°F and 86°F) away from sources of moisture such as a sink or other damp place. Heat and moisture may reduce the effectiveness of VIRACEPT Oo not keep medicine that is out of date or that you no longer need. Be sure that if you throw any medicine away, it is out of the reach of children. Discuss all questions about your health with your doctor if you have questions about VIRACEPT or any other medication you are taking, ask your doctor nurse or pharmacist. You can also call 1 888.VIRACEPT (1 888 847.2237) toll free. The following are registered trademarks ot their respective manufacturers: Retrovir, Epivir/Glaxo Wellcome Oncology/HIV; Zerit, Videx/Bnstol-Myers Squibb Oncology Invirase, Versed/Roche Laboratories Inc; Seldane, Rifadin. Rifamate, Rrfater/Hoechst Marion Rous'sel; Hismanal. Propulsid/Janssen Pharmaceutica Inc; Halcion, Mycobutin/Pharmacia & Upjohn Co; Rimactane, Tegretol/CibaGeneva Pharmaceuticals; Viramune/Roxane Laboratories. Inc- Dilantin/Parke-Davis; Crixivan/Merck & Co, Inc; Imodium A-D/McNeil Consumer Products Co; Cordarone/Wyeth-Ayerst Laboratories; Quinaglute/Berlex Laboratories, Cardioquin/The Purdue Frederick Co; Quinidex/A H Robins Co. Inc; Cafergot/Novartis Pharmaceuticals Corp Norvir is a trademark of Abbott Laboratories. Issued 11/13/97 CALL1.MJ.VWACEPT VIRACEPT Is i registered trademark of Agouron Ptiariruceuuctls Inc C0P)^.O.999Aw»™^onK.«iat,.te,,rtaBBmraa l, j^ c*>n* 9M37. USA i Agouron
File Name uhlib_31485329_n1005_004.jpg